deltatrials
Completed PHASE2 NCT00003860

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer

Intensive Chemotherapy With Peripheral Blood Stem Cell Support for Small Cell Lung Cancer

Sponsor: UNICANCER

Conditions Lung Cancer
Interventions carboplatin etoposide filgrastim ifosfamide in vitro-treated peripheral blood stem cell transplantation
Updated 7 times since 2017 Last updated: Feb 19, 2021 Started: Sep 30, 1998 Primary completion: Aug 31, 2000 Completion: Sep 30, 2005

Listed as NCT00003860, this PHASE2 trial focuses on Lung Cancer and remains completed. Sponsored by UNICANCER, it has been updated 7 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2021 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  5. Jan 2021 — Mar 2021 [monthly]

    Unknown Status PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Sep 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UNICANCER
Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Besançon, France, Bordeaux, France, Briis-sous-Forges, France, Dijon, France, Grenoble, France, Lyon, France, Marseille, France, Montpellier, France, Nice, France, Paris, France and 8 more location s